ArticleCureus2026
Discharge Prescription of Renin-Angiotensin System Inhibitors After Hyperkalemia and Its Association With Mortality and Dialysis Outcomes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication changes at hospital discharge may influence post-discharge outcomes. Renin-angiotensin system inhibitors (RASi) are frequently discontinued during hospitalization for hyperkalemia; however, guidance regarding discharge prescribing is limited. We evaluated the association between RASi prescription at discharge and post-discharge outcomes in patients hospitalized with hyperkalemia.
methodsIn this single-center retrospective cohort study at a large tertiary hospital, adults admitted between 2005 and 2020 with a potassium level > 5.5 mEq/L while receiving chronic RASi therapy were included and followed through 2022. Exposure was defined as prescription versus non-prescription of RASi at discharge. Propensity score matching was used among survivors of the first hospitalization to balance baseline characteristics. Kaplan-Meier and multivariable Cox models were used to assess all-cause mortality and chronic dialysis.
resultsAmong 12,326 patients with confirmed hyperkalemia, 9,051 survived the index hospitalization; 4,388 were included after matching (2,194 per group). Prescription of RASi at discharge was associated with lower mortality (401 (18.3%) vs 642 (29.3%); hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.55-0.71) but a higher risk of chronic dialysis initiation (167 (8.2%) vs. 111 (5.7%); HR, 1.57; 95% CI, 1.23-1.99).
conclusionsIn patients hospitalized with hyperkalemia, discharge prescription of RASi was associated with lower mortality but a higher incidence of chronic dialysis initiation. Dialysis initiation may reflect both progression of renal disease and longer survival among patients discharged on RASi therapy. Given the observational study design, these findings should be interpreted as associations rather than causal effects and underscore the complex risk-benefit considerations surrounding discharge medication decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.